Cargando…
Can the plasma PD-1 levels predict the presence and efficiency of tumor-infiltrating lymphocytes in patients with metastatic melanoma?
BACKGROUND: The immune response in melanoma patients is locally affected by presence of tumor-infiltrating lymphocytes (TILs), generally divided into brisk, nonbrisk, and absent. Several studies have shown that a greater presence of TILs, especially brisk, in primary melanoma is associated with a be...
Autores principales: | Incorvaia, Lorena, Badalamenti, Giuseppe, Rinaldi, Gaetana, Iovanna, Juan Lucio, Olive, Daniel, Swayden, Mirna, Terruso, Lidia, Vincenzi, Bruno, Fulfaro, Fabio, Bazan, Viviana, Russo, Antonio, Fanale, Daniele |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
SAGE Publications
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6535916/ https://www.ncbi.nlm.nih.gov/pubmed/31205506 http://dx.doi.org/10.1177/1758835919848872 |
Ejemplares similares
-
Prognostic Role of Plasma PD-1, PD-L1, pan-BTN3As and BTN3A1 in Patients Affected by Metastatic Gastrointestinal Stromal Tumors: Can Immune Checkpoints Act as a Sentinel for Short-Term Survival?
por: Fanale, Daniele, et al.
Publicado: (2021) -
Baseline plasma levels of soluble PD-1, PD-L1, and BTN3A1 predict response to nivolumab treatment in patients with metastatic renal cell carcinoma: a step toward a biomarker for therapeutic decisions
por: Incorvaia, Lorena, et al.
Publicado: (2020) -
A “Lymphocyte MicroRNA Signature” as Predictive Biomarker of Immunotherapy Response and Plasma PD-1/PD-L1 Expression Levels in Patients with Metastatic Renal Cell Carcinoma: Pointing towards Epigenetic Reprogramming
por: Incorvaia, Lorena, et al.
Publicado: (2020) -
Prognostic role of soluble PD-1 and BTN2A1 in overweight melanoma patients treated with nivolumab or pembrolizumab: finding the missing links in the symbiotic immune-metabolic interplay
por: Incorvaia, Lorena, et al.
Publicado: (2023) -
Prognostic significance of circulating PD-1, PD-L1, pan-BTN3As, BTN3A1 and BTLA in patients with pancreatic adenocarcinoma
por: Bian, Benjamin, et al.
Publicado: (2019)